SUKI PARKS: Open Payments
NPI 1619002508 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$293 in 12 payments from 9 companies in 2025. Trend: 2023 $259 · 2024 $292 · 2025 $293
Food & beverage: $293
| Company | Payments | Amount |
|---|---|---|
| Exelixis Inc. | 2 | $58 |
| Azurity Pharmaceuticals, Inc. | 2 | $42 |
| AstraZeneca Pharmaceuticals LP | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| ABBVIE INC. | 1 | $27 |
| Lilly USA, LLC | 1 | $26 |
| Merck Sharp & Dohme LLC | 1 | $26 |
| Incyte Corporation | 1 | $26 |
| Janssen Biotech, Inc. | 1 | $14 |
Products named: CABOMETYX, CALQUENCE, LIBTAYO, IMBRUVICA, VERZENIO, KEYTRUDA, MONJUVI, VIVIMUSTA.
Industry payments across MD — which companies pay providers there.
